Allarity Therapeutics CFO resigns; appoints Alexander Epshinsky; boosts ATM capacity to $50M

Allarity Therapeutics, Inc.

Joan Brown resigned as CFO effective Sept 12, 2024; no disagreement with company.
Alexander Epshinsky appointed CFO effective Sept 12; $340k base salary, $50k signing bonus, $160k RSUs (3-year vest).
ATM sales agreement second amendment increases placement shares capacity to $50 million.
Company states it paused financing but now, with new CFO, will pursue financing opportunities.

item 1.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Joan Y. Brown

Chief Financial Officer

ALLR · Allarity Therapeutics, Inc.

Effective: 2024-09-12
Successor: Alexander Epshinsky
Filed: September 13, 2024, 7:59 PM ET

On September 12, 2024, the Company received a notice of resignation from Joan Y. Brown, its Chief Financial Officer, effective September 12, 2024.

Appointed

Alexander Epshinsky

Chief Financial Officer

ALLR · Allarity Therapeutics, Inc.

Effective: 2024-09-12
Filed: September 13, 2024, 7:59 PM ET

On September 12, 2024, the Board of Directors (the “Board”) of the Company approved the appointment of Alexander Epshinsky as the Chief Financial Officer of the Company as of September 12, 2024, succeeding Ms. Brown.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Joan Y. Brown resigned as Chief Financial Officer at Allarity Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On September 12, 2024, the Company received a notice of resignation from Joan Y. Brown, its Chief Financial Officer, effective September 12, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Alexander Epshinsky was appointed as Chief Financial Officer at Allarity Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On September 12, 2024, the Board of Directors (the “Board”) of the Company approved the appointment of Alexander Epshinsky as the Chief Financial Officer of the Company as of September 12, 2024, succeeding Ms. Brown.

View on SEC.gov

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-078294

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.